Nom du médicament (en anglais)

Commentaire (en anglais)

Annexe

Date

Including but not limited to acenocoumarol when sold or recommended as anticoagulants.

I
Déc / 13

including but not limited to mesalazine

I
Déc / 13
I
Déc / 13
I
Déc / 13

including but not limited to abiraterone acetate

I
Déc / 13

for human use

I
Déc / 13

when recommended for administration by intravenous injection

I
Déc / 13

When sold in oral, fixed-dose combinations, in package sizes containing 20,000 mg or less of acetaminophen and 6,000 mg or less of ibuprofen*
*Note that this listing does not apply to products containing ibuprofen that would meet the criteria to be included on the Prescription Drug list, as these would require a prescription

III
Juil / 20

When sold in oral, fixed-dose combinations, in package sizes containing either more than 20,000 mg of acetaminophen or more than 6,000 mg of ibuprofen*
*Note that this listing does not apply to products containing ibuprofen that would meet the criteria to be included on the Prescription Drug list, as these would require a prescription

II
Juil / 20

up to and including 650 mg per unit, in package sizes containing no more than 50 units

U
Jan / 03

in strengths of greater than 650 mg per unit or in package sizes of more than 50 units

III
Jan / 03

in immediate release tablets, capsules, suppositories or liquid

U
Sep / 99

for human use

I
Déc / 13
II
Sep / 98
I
Déc / 13
I
Déc / 13
I
Déc / 13

In injectable form

II
Sep / 98

oral preparations containing 80 mg or less per dosage unit and intended for pediatric use or rectal preparations containing 150 mg or less per dosage unit, in package sizes containing no more than 1.92 g of acetylsalicylic acid.

II
Fév / 02

in products for oral use in strengths of 325mg and 500mg per dosage unit

U
Oct / 00

in products intended for oral adult use in strengths of 81 mg per dosage unit and 650 mg or greater per dosage unit, and in rectal preparations containing more than 150 mg per dosage unit

III
Oct / 00
I
Déc / 13

including but not limited to adefovir dipivoxil

I
Déc / 13

when sold or recommended for administration by intravenous injection

I
Déc / 13

for parenteral use

II
Sep / 98

for human use including but not limited to: Betamethasone valerate, betamethasone sodium, betamethasone phosphate, betamethasone dipropionate, budesonide, ciclesonide, clobetasone, cortisone, dexamethasone sodium, dexamethasone phosphate, dexamethasone acetate, difluprednate, fludrocortisone acetate, flunisolide, fluticasone propionate, fluticasone furoate, hydrocortisone acetate, hydrocortisone aceponate, hydrocortisone sodium, methylprednisolone acetate, methylprednisolone, methylprednisolone succinate, methylprednisolone sodium, mometasone furoate, prednisolone acetate, prednisolone sodium, prednisolone phosphate, prednisone, triamcinolone acetonide, triamcinolone hexacetonide except: (a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1.0% or less hydrocortisone in preparations for topical use on the skin; or (b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other nonprescription medicinal ingredient that provides 1.0% or less hydrocortisone in preparations for topical use on the skin; or (c) clobetasone butyrate when sold in a concentration of 0.05% in cream preparations for topical use on the skin; or (d) triamcinolone acetonide in a nasal spray that delivers 55 microgram (mcg)/spray for those 12 years of age and older; or, (e) mometasone furoate for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 12 years of age and older; or (f) fluticasone propionate for the treatment of allergic rhinitis in a nasal spray that delivers 50 microgram/spray for those 18 years of age and older.

I
Août / 16
I
Déc / 13
I
Août / 14
I
Avr / 07
I
Déc / 14
I
Août / 15
I
Déc / 13
I
Déc / 13
I
Déc / 13
I
Déc / 13
I
Déc / 13
I
Août / 16
I
Déc / 13
II
Sep / 98
I
Déc / 13
I
Déc / 13

including but not limited to citric acid, glycolic acid, lactic acid, malic acid, mandelic acid, ammonium glycolate, glycolic acid + ammonium glycolate, alpha-hydroxyethanoic acid + ammonium alpha-hydroxyethanoate, alpha-hydroxyoctanoic acid, alpha-hydroxycaprylic acid, hydroxycaprylic acid, mixed fruit acid, triple fruit acid, tri-alpha hydroxy fruit acids, alpha hydroxy and botanical complex, l-alpha hydroxy acid, glycomer in cross-linked fatty acids alpha nutrium, when sold in topical formulations containing alpha hydroxy acids alone or in combination at concentrations of greater than 30% and/or with a pH lower than 3.0, except when sold to be applied to warts, corns or calluses

I
Déc / 14

including but not limited to alfaxalone, alphaxolone

I
Déc / 13

including but not limited to tenecteplase

I
Déc / 13
I
Déc / 13
I
Déc / 13

in injectable form

I
Sep / 98
I
Déc / 13
I
Déc / 13

Including: Dimethylaminodiphenylbutanonitrile; Dipipanone; Isomethadone; Methadone; Normethadone; Norpipanone; Phenadoxone
 

I
Juin / 02

PDL, including but not limited to amikacin sulfate

I
Déc / 13

in injectable form

I
Sep / 99
I
Déc / 13
I
Déc / 13
I
Déc / 13

for human use

I
Déc / 13

including but not limited to dronedarone

I
Déc / 13
I
Déc / 13
I
Juin / 22

Footnotes

C – Drug is listed in the Schedule to Part G of the Food and Drug Regulations under the Controlled Drugs and Substances Act
N – Drug is listed in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
NR – Drug has not been reviewed by the NDSAC
PDL – Drug is listed in the Health Canada Prescription Drug List
TS – Drug is listed in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
CR – Drug has been recommended for addition to the Controlled Drugs and Substances Act